期刊文献+

Flt3配体在肿瘤免疫治疗中的应用 被引量:1

Application of Flt3 ligand for tumor immunotherapy
下载PDF
导出
摘要 肿瘤是一类严重威胁人类健康和生命的疾病,因此,有关肿瘤早期诊断和治疗一直是科学研究的热点问题。近年针对肿瘤患者的免疫监视功能缺损,以提高树突状细胞(DC)、T细胞及NK细胞介导的肿瘤免疫治疗为策略的癌症治疗方法已经取得了多项进展,基于Flt3配体(FL)免疫治疗就是其中之一。FL是主要表达于造血干细胞/祖细胞上的Ⅲ型酪氨酸激酶受体Flt3的配体,是一种与早期造血调控有关的生长因子。FL联合其他细胞因子,能够在体内外显著地扩增DC,刺激T细胞和NK细胞增殖,为肿瘤免疫治疗提供了良好的基础。目前采用FL治疗乳腺肿瘤、前列腺肿瘤、颅内肿瘤等,已经显示了其在肿瘤免疫治疗领域中的良好临床应用前景。
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2009年第2期393-396,共4页 Journal of Jilin University:Medicine Edition
基金 国家自然科学基金资助课题(30571688)
  • 相关文献

参考文献27

  • 1Lyman SD, James L, Vanden Bos T, et al. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells [J]. Cell, 1993, 75 (6): 1157-1167.
  • 2Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human Flt3 Is expressed at the hematopoietic stem cell and the granulocyte/macroph -age progenitor stages to maintain Cell Survival [J]. J Immunol, 2008, 180: 7358-7367.
  • 3O' Neill DW, Adams S, Bhardwaj N, et al. Manipulating dendritic cell biology for the active immunotherapy of cancer [J]. Blood, 2004, 104 (8): 2235-2246.
  • 4Bohannon J, Cui YW, Cox R, et at. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection [ J ]. J Immunol, 2008, 180 (5) : 3038-3048.
  • 5Miller G, Pillarisetty V G, Shah A Bet al. Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties [ J ]. J Immunol, 2003, 170 (7): 3554-3564.
  • 6Karsunky i-I, Merad M, Cozzio A, et al. Flt3 Ligand regulates dendritic cell development from Flt3 + lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo [J]. J Exp Med, 2003, 198 (2): 305-313.
  • 7Fukuda S, Broxmeyer HE, Pelus LM. Flt3 ligant and the Flt3 receptor regulate hematopoietic cell by modulating the SDF-1 alpha (CXCL12) /CXCR4 axis [J]. Blood, 2005, 105 (8): 3117-3126.
  • 8Kalberer CP, Siegler U, Wodnar-Filipowicz A. Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells [J]. Blood, 2003, 102 (1) : 127-135.
  • 9Perez SA, Mahaira LG, Sotiropoulou DA, et al. Effect of IL-21 on NK cells derived from different umbilical cord blood populations [J]. Int Immunol, 2006, 18 (1): 49-58.
  • 10Sitnicka E, Buza-Vidas N, Ahlenius H, et al. Critical role of FLT3 ligand in IL-7 receptor-independent T lymphopoiesis and regulation of lymphoid-primed multipotent progenitors [J]. Blood, 2007, 110 (8): 2955-2964

同被引文献12

  • 1罗道升,戴宇平.树突状细胞相关基础研究进展[J].国外医学(免疫学分册),2005,28(1):51-55. 被引量:18
  • 2吴雨岗,汪良,张雁云.人外周血树突状细胞的体外扩增、鉴定及内吞能力的测定[J].中国血液流变学杂志,2004,14(4):444-447. 被引量:6
  • 3Shortman K,Liu YJ. Mouse and human dendritic cell subtypes [J]. Nature Rev Immunol,2002 ;2 ( 3 ) : 151-61.
  • 4King GD, Kroeger KM, Bresee C J, et al. Flt3 L in combination with HSV1 - TK-mediated gene therapy reverses brain tumor-induced behavioral deficits [J]. Mol Ther,2008 ;16(4) :682-90.
  • 5Ashour AE, Turnquist HR, Burns N, et al. Flt3 ligand delivered in a pluronic formulation prolongs the survival of mice with orthotopic pancreatic adenocarcinoma [J]. Cancer Biother Radiopharm,2007 ;22(2) :235-8.
  • 6Wang H, Dai J, Hou S, et al. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy [J]. Cancer Gene Ther,2005 ; 12(9) :769-77.
  • 7Rosenzwajg M, Camus S, Guigon M,et al. The influence of IL-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34 + progenitor cells[J]. Exp Hematol, 1998 ;26 ( 1 ) :63-72.
  • 8Chui S, Clay TM, Mosca PJ ,et al. Flt3-1igand as a vaccine adjuvant : resuits in a study of fh3-ligand plus tetanus toxoid immunization [J]. J Appl Res,2004;4(4) :536-49.
  • 9Howard C J, Hope JC, Stephens SA, et al. Costimulation and modulation of the ensuing immune response [J]. Vet Immunol Immunopathol, 2002 ;87 ( 3-4 ) : 123-30.
  • 10Hoffmann TK, Meidenbauer N, Muller-Berghaus J, et al. Proinflammatory cytokines and CD40 ligand enhance cross-presentation and cross-prim- ing capability of human dendritic cells internalizing apoptotic cancer cells [J]. J Immunother,2001 ;24 (2) : 162-71.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部